Shixia Wang

Conigen Bioscience Inc. is a science-driven life science tools company that integrates state-of-art immunology, virology, molecular biology and cell biology to create new reagents and high-quality assays, for a broad range of novel targets to enable new drug modalities, from discovery to development to manufacturing. Dr. Jean Qiu is the Chief Executive Officer of Conigen Bioscience, Inc. Previously, Dr. Qiu was the Founder & Chief Technology Officer of Nexcelom Bioscience. From the basement of her home, she started Nexcelom in 2003, with the goal of automating manual cell counting on the biologist’s lab bench using image cytometry technologies. Nexcelom product portfolio expanded to include cell counting and cell-based assay instruments, software, consumables and reagent kits, which are distributed globally. Nexcelom was acquired by PerkinElmer in 2021. Dr. Qiu has published over 50 papers in peer-reviewed academic journals and holds more than 35 patents. https://www.linkedin.com/in/jean-qiu-4ab7492/ Dr. Shixia Wang is a Co-Founder and the Chief Scientific Officer of Conigen Bioscience, Inc. Previously, Dr. Wang was a professor at University of Massachusetts Medical School, focused on vaccine and antibody research and discovery since 2000. After 2021, as the senior director of immunology in a vaccine company, she successfully enhanced the team and capabilities, built a state-of-art immunology lab from scratch in a record time. Dr. Wang has extensive knowledge and expertise in vaccinology, immunology, infectious disease, virology, microbiology and antibody research. Her rich experiences cover immunogen design, modern immunological and virological assays, bioanalytical and GLP assay development and management, toxicology and clinical study design, process development for DNA and protein vaccine GMP manufacturing and PreIND/IND filing. Dr. Wang has published over 160 peer-reviewed papers and holds 12 patents. https://www.linkedin.com/in/shixia-wang-phd-7b728820/